Bright Net Receivables vs Total Current Liabilities Analysis

DRUG Stock

USD 32.38 0.29 0.89%

Bright Minds financial indicator trend analysis is way more than just evaluating Bright Minds Biosciences prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Bright Minds Biosciences is a good investment. Please check the relationship between Bright Minds Net Receivables and its Total Current Liabilities accounts. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Bright Minds Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment.

Net Receivables vs Total Current Liabilities

Net Receivables vs Total Current Liabilities Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Bright Minds Biosciences Net Receivables account and Total Current Liabilities. At this time, the significance of the direction appears to have almost no relationship.

The correlation between Bright Minds' Net Receivables and Total Current Liabilities is 0.12. Overlapping area represents the amount of variation of Net Receivables that can explain the historical movement of Total Current Liabilities in the same time period over historical financial statements of Bright Minds Biosciences, assuming nothing else is changed. The correlation between historical values of Bright Minds' Net Receivables and Total Current Liabilities is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Net Receivables of Bright Minds Biosciences are associated (or correlated) with its Total Current Liabilities. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Current Liabilities has no effect on the direction of Net Receivables i.e., Bright Minds' Net Receivables and Total Current Liabilities go up and down completely randomly.

Correlation Coefficient

0.12

Relationship Direction	Positive
Relationship Strength	Insignificant

View All Relationships

Net Receivables

Total Current Liabilities

Total Current Liabilities is an item on Bright Minds balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Bright Minds Biosciences are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Most indicators from Bright Minds' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Bright Minds Biosciences current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Bright Minds Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment.

The current Selling General Administrative is estimated to decrease to about 1.3 M. The current Issuance Of Capital Stock is estimated to decrease to about 1 M

Bright Minds fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Tangible Assets	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Common Stock Shares Outstanding	Other Stockholder Equity	Total Liab	Total Current Assets	Intangible Assets	Common Stock	Good Will	Non Current Liabilities Total	Other Current Assets	Net Invested Capital	Capital Stock	Net Working Capital	Net Receivables	Short Term Investments
Total Assets		0.37	0.77	1.0	0.97	-0.99	-0.64	0.75	1.0	-0.29	-0.79	1.0	0.52	0.38	0.76	1.0	0.85	0.82	-0.89	0.44	0.44	0.99	0.82	0.99	-0.18	-0.29
Other Current Liab	0.37		0.82	0.33	0.26	-0.39	-0.26	0.87	0.36	0.61	-0.02	0.36	0.1	0.98	0.83	0.37	0.28	0.34	-0.36	-0.02	0.65	0.32	0.32	0.32	0.53	0.16
Total Current Liabilities	0.77	0.82		0.74	0.69	-0.76	-0.64	0.97	0.76	0.2	-0.34	0.76	0.42	0.86	1.0	0.77	0.73	0.71	-0.77	0.05	0.52	0.74	0.71	0.74	0.12	-0.23
Total Stockholder Equity	1.0	0.33	0.74		0.97	-0.99	-0.63	0.72	1.0	-0.32	-0.81	1.0	0.52	0.33	0.73	1.0	0.85	0.81	-0.89	0.46	0.42	1.0	0.81	1.0	-0.2	-0.29
Net Tangible Assets	0.97	0.26	0.69	0.97		-0.95	-0.75	0.65	0.97	-0.3	-0.73	0.97	0.69	0.28	0.68	0.97	0.91	0.91	-0.94	0.32	0.26	0.96	0.9	0.96	-0.36	-0.33
Net Debt	-0.99	-0.39	-0.76	-0.99	-0.95		0.58	-0.76	-0.99	0.3	0.83	-0.99	-0.46	-0.39	-0.75	-0.99	-0.8	-0.78	0.86	-0.51	-0.51	-0.98	-0.77	-0.98	0.1	0.18
Retained Earnings	-0.64	-0.26	-0.64	-0.63	-0.75	0.58		-0.51	-0.64	-0.08	0.11	-0.64	-0.92	-0.35	-0.63	-0.64	-0.94	-0.93	0.92	0.38	0.25	-0.64	-0.95	-0.64	0.65	0.59
Accounts Payable	0.75	0.87	0.97	0.72	0.65	-0.76	-0.51		0.74	0.19	-0.39	0.74	0.33	0.89	0.97	0.74	0.61	0.64	-0.69	0.18	0.67	0.7	0.63	0.69	0.29	-0.01
Cash	1.0	0.36	0.76	1.0	0.97	-0.99	-0.64	0.74		-0.29	-0.8	1.0	0.52	0.37	0.75	1.0	0.85	0.82	-0.89	0.45	0.43	1.0	0.82	1.0	-0.19	-0.29
Non Current Assets Total	-0.29	0.61	0.2	-0.32	-0.3	0.3	-0.08	0.19	-0.29		0.63	-0.29	0.05	0.54	0.21	-0.29	-0.09	-0.03	0.09	-0.54	-0.01	-0.31	-0.03	-0.31	0.25	0.06
Non Currrent Assets Other	-0.79	-0.02	-0.34	-0.81	-0.73	0.83	0.11	-0.39	-0.8	0.63		-0.8	-0.07	0.03	-0.32	-0.79	-0.42	-0.38	0.48	-0.87	-0.57	-0.8	-0.37	-0.8	-0.05	-0.05
Cash And Short Term Investments	1.0	0.36	0.76	1.0	0.97	-0.99	-0.64	0.74	1.0	-0.29	-0.8		0.52	0.37	0.75	1.0	0.85	0.82	-0.89	0.45	0.43	1.0	0.82	1.0	-0.19	-0.29
Common Stock Shares Outstanding	0.52	0.1	0.42	0.52	0.69	-0.46	-0.92	0.33	0.52	0.05	-0.07	0.52		0.18	0.42	0.52	0.83	0.91	-0.81	-0.38	-0.36	0.5	0.9	0.5	-0.7	-0.45
Other Stockholder Equity	0.38	0.98	0.86	0.33	0.28	-0.39	-0.35	0.89	0.37	0.54	0.03	0.37	0.18		0.87	0.37	0.34	0.4	-0.41	-0.13	0.57	0.32	0.38	0.31	0.46	0.1
Total Liab	0.76	0.83	1.0	0.73	0.68	-0.75	-0.63	0.97	0.75	0.21	-0.32	0.75	0.42	0.87		0.76	0.72	0.7	-0.76	0.04	0.52	0.72	0.7	0.72	0.13	-0.22
Total Current Assets	1.0	0.37	0.77	1.0	0.97	-0.99	-0.64	0.74	1.0	-0.29	-0.79	1.0	0.52	0.37	0.76		0.85	0.82	-0.89	0.44	0.44	1.0	0.82	0.99	-0.18	-0.29
Intangible Assets	0.85	0.28	0.73	0.85	0.91	-0.8	-0.94	0.61	0.85	-0.09	-0.42	0.85	0.83	0.34	0.72	0.85		0.96	-0.98	-0.06	-0.03	0.86	0.98	0.86	-0.56	-0.6
Common Stock	0.82	0.34	0.71	0.81	0.91	-0.78	-0.93	0.64	0.82	-0.03	-0.38	0.82	0.91	0.4	0.7	0.82	0.96		-0.97	-0.08	0.01	0.8	1.0	0.79	-0.5	-0.41
Good Will	-0.89	-0.36	-0.77	-0.89	-0.94	0.86	0.92	-0.69	-0.89	0.09	0.48	-0.89	-0.81	-0.41	-0.76	-0.89	-0.98	-0.97		-0.02	-0.09	-0.89	-0.98	-0.88	0.46	0.45
Non Current Liabilities Total	0.44	-0.02	0.05	0.46	0.32	-0.51	0.38	0.18	0.45	-0.54	-0.87	0.45	-0.38	-0.13	0.04	0.44	-0.06	-0.08	-0.02		0.71	0.45	-0.11	0.45	0.41	0.38
Other Current Assets	0.44	0.65	0.52	0.42	0.26	-0.51	0.25	0.67	0.43	-0.01	-0.57	0.43	-0.36	0.57	0.52	0.44	-0.03	0.01	-0.09	0.71		0.39	-0.02	0.4	0.8	0.51
Net Invested Capital	0.99	0.32	0.74	1.0	0.96	-0.98	-0.64	0.7	1.0	-0.31	-0.8	1.0	0.5	0.32	0.72	1.0	0.86	0.8	-0.89	0.45	0.39		0.8	1.0	-0.23	-0.36
Capital Stock	0.82	0.32	0.71	0.81	0.9	-0.77	-0.95	0.63	0.82	-0.03	-0.37	0.82	0.9	0.38	0.7	0.82	0.98	1.0	-0.98	-0.11	-0.02	0.8		0.8	-0.53	-0.48
Net Working Capital	0.99	0.32	0.74	1.0	0.96	-0.98	-0.64	0.69	1.0	-0.31	-0.8	1.0	0.5	0.31	0.72	0.99	0.86	0.79	-0.88	0.45	0.4	1.0	0.8		-0.23	-0.35
Net Receivables	-0.18	0.53	0.12	-0.2	-0.36	0.1	0.65	0.29	-0.19	0.25	-0.05	-0.19	-0.7	0.46	0.13	-0.18	-0.56	-0.5	0.46	0.41	0.8	-0.23	-0.53	-0.23		0.72
Short Term Investments	-0.29	0.16	-0.23	-0.29	-0.33	0.18	0.59	-0.01	-0.29	0.06	-0.05	-0.29	-0.45	0.1	-0.22	-0.29	-0.6	-0.41	0.45	0.38	0.51	-0.36	-0.48	-0.35	0.72

Click cells to compare fundamentals

Bright Minds Account Relationship Matchups

Bright Minds fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	880.2K	20.0M	12.1M	6.9M	7.9M	8.8M
Other Current Liab	12.5K	42K	158.2K	25K	28.8K	27.3K
Total Current Liabilities	150.9K	638.6K	1.5M	280.9K	323.0K	567.5K
Total Stockholder Equity	729.3K	19.4M	10.5M	6.6M	7.6M	8.2M
Net Debt	(799.9K)	(19.8M)	(11.5M)	(6.7M)	(6.0M)	(6.3M)
Retained Earnings	(559.1K)	(9.2M)	(24.2M)	(31.5M)	(28.4M)	(27.0M)
Accounts Payable	138.4K	596.6K	1.2M	182.3K	209.7K	199.2K
Cash	799.9K	19.8M	11.6M	6.7M	7.8M	8.6M
Cash And Short Term Investments	799.9K	19.8M	11.6M	6.7M	7.8M	8.6M
Liabilities And Stockholders Equity	880.2K	20.0M	12.1M	6.9M	7.9M	8.8M
Other Stockholder Equity	0.0	(33.7K)	10.5T	831.8K	956.6K	908.8K
Total Liab	150.9K	638.6K	1.5M	280.9K	323.0K	583.3K
Total Current Assets	878.2K	20.0M	11.9M	6.8M	7.8M	8.7M
Accumulated Other Comprehensive Income	161.3K	1.6M	2.5M	3.4M	3.9M	4.1M
Common Stock	980.7K	27.1M	32.2M	33.9M	39.0M	20.8M

Currently Active Assets on Macroaxis

RSI	Rush Street Interactive
OKTA	Okta Inc
BAC	Bank of America
S	SentinelOne
WD	Walker Dunlop

When determining whether Bright Minds Biosciences is a strong investment it is important to analyze Bright Minds' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Bright Minds' future performance. For an informed investment choice regarding Bright Stock, refer to the following important reports:

How To Invest In Bright

Details

Is Bright Stock a good investment?

Details

What is Bright Minds' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Bright Minds Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment.

You can also try the My Watchlist Analysis module to analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bright Minds. If investors know Bright will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bright Minds listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(0.63)

Return On Assets

(0.29)

Return On Equity

(0.52)

The market value of Bright Minds Biosciences is measured differently than its book value, which is the value of Bright that is recorded on the company's balance sheet. Investors also form their own opinion of Bright Minds' value that differs from its market value or its book value, called intrinsic value, which is Bright Minds' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bright Minds' market value can be influenced by many factors that don't directly affect Bright Minds' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Bright Minds' value and its price as these two are different measures arrived at by different means. Investors typically determine if Bright Minds is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bright Minds' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Bright Net Receivables vs Total Current Liabilities Analysis

Net Receivables vs Total Current Liabilities

Net Receivables vs Total Current Liabilities Correlation Analysis

Correlation Coefficient

Net Receivables

Total Current Liabilities

Bright Minds fundamental ratios Correlations

Bright Minds Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Bright Minds fundamental ratios Accounts

Currently Active Assets on Macroaxis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Stockholder Equity	+ 1.0	Total Assets
Cash	+ 1.0	Total Assets
Cash And Short Term Investments	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Total Liab	+ 1.0	Total Current Liabilities
Cash	+ 1.0	Total Stockholder Equity

Total Current Assets	- 0.99	Net Debt
Cash And Short Term Investments	- 0.99	Net Debt
Cash	- 0.99	Net Debt
Net Debt	- 0.99	Total Stockholder Equity
Net Debt	- 0.99	Total Assets
Capital Stock	- 0.98	Good Will